`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`LIQUIDIA TECHNOLOGIES, INC.,
`
`Petitioner,
`
`v.
`
`UNITED THERAPEUTICS CORPORATION,
`
`Patent Owner.
`
`_______________
`
`Case IPR2021-00406
`Patent 10,716,793
`_______________
`
`JOINT ERRATA
`
`
`
`
`
`
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`Parties’ Joint Errata
`
`Pursuant to the Board’s email dated April 20, 2022, Petitioner and Patent
`
`
`
`Owner hereby identify errata to the documents identified below.
`
`Party
`requesting
`change
`Patent
`Owner
`
`Paper
`No.
`
`Page
`No.
`
`14
`
`55
`(Sur-
`reply)
`
`Patent
`Owner
`
`Patent
`Owner
`
`15
`
`16
`
`55
`(Sur-
`reply)
`55
`(Sur-
`reply)
`
`Current text
`
`New text1
`
`Compare EX2197,
`181:3-182:6; EX2102,
`27 (DeVilbiss manual:
`output rates of 3.0 and
`2.5 mL/min) with
`EX1107,
`¶33; EX1099 (DeVilbiss
`testing: 0.67-1.14
`mL/min); compare
`EX2197,
`164:5-14, 174:17-20;
`EX2100, 28; EX2101,
`28 (Multisonic manual:
`rates of 0.6 and 0.5
`mL/min) with EX1062
`(Multisonic testing:
`0.140 mL/min delivered
`dose rate).
`EX2197, 173:19-174:9;
`cf. EX2053, ¶81.
`
`Compare EX2099,
`181:3-182:6; EX2102,
`27 (DeVilbiss manual:
`output rates of 3.0 and
`2.5 mL/min) with
`EX1107,
`¶33; EX1099 (DeVilbiss
`testing: 0.67-1.14
`mL/min); compare
`EX2099,
`164:5-14, 174:17-20;
`EX2100, 28; EX2101,
`28 (Multisonic manual:
`rates of 0.6 and 0.5
`mL/min) with EX1062
`(Multisonic testing:
`0.140 mL/min delivered
`dose rate).
`EX2099, 173:19-174:9;
`cf. EX2053, ¶81.
`
`EX2197, 158:6-8,
`158:24-159:3.
`
`EX2099, 158:6-8,
`158:24-159:3.
`
`
`1 Changed text is shown by bold and underlined text.
`1
`
`
`
`
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`Party
`requesting
`change
`Patent
`Owner
`
`Paper
`No.
`
`Page
`No.
`
`16
`
`55
`(Sur-
`reply)
`
`Patent
`Owner
`
`17
`
`55
`(Sur-
`reply)
`
`Patent
`Owner
`
`Petitioner
`
`55
`(Sur-
`reply)
`60
`
`17
`
`3
`
`Parties’ Joint Errata
`
`Current text
`
`New text1
`
`Lieberman 2006
`Lieberman 2006
`(EX2103; EX2099,
`(EX2103; EX2197,
`198:15-199:6) tested a
`198:15-199:6) tested a
`MyNeb ultrasonic
`MyNeb ultrasonic
`nebulizer using 2.5 mg
`nebulizer using 2.5 mg
`albuterol sulfate, 20 mg
`albuterol sulfate, 20 mg
`cromolyn sodium, and
`cromolyn sodium, and
`0.5 mg ipratropium
`0.5 mg ipratropium
`bromide that yielded
`bromide that yielded
`1.73 mg, 10.3 mg, and
`1.73 mg, 10.3 mg, and
`0.3 mg of the three
`0.3 mg of the three
`drugs.
`drugs.
`EX2097, 101:3-15
`EX2197, 101:3-15
`(explaining his
`(explaining his
`calculations provide a
`calculations provide a
`range that is “bigger
`range that is “bigger
`than plus/minus 15
`than plus/minus 15
`percent”).
`percent”).
`EX2197, 104:14-105:1. EX2097, 104:14-105:1.
`
`N/A (adding to end of
`document)
`
`3) Relying on the
`portions of Ex. 2099
`related to Exs. 2100-
`2013:
`a. P. 14:
`“Discrepancies” to
`“dose rate).”
`b. P. 15: “Indeed, Dr.
`Gonda agreed” to
`“173:19-174:9”
`c. P.16: “Lieberman
`2006” to “respectively.”
`4) The materials
`objected to by Petitioner
`above as items 3)a.-c.
`
`Patent
`Owner
`
`62
`
`3
`
`N/A (adding to end of
`document)
`
`
`
`2
`
`
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`Party
`requesting
`change
`
`Paper
`No.
`
`Page
`No.
`
`Parties’ Joint Errata
`
`Current text
`
`New text1
`
`are responsive to at least
`the following portions of
`Petitioner’s Reply and
`exhibits cited therein:
`o Pages 11-12
`(regarding nebulizer
`efficiency and loss
`and expected
`nebulizer output
`rates).
`o Pages 12-13
`(regarding factors
`that influence dose
`delivery and the
`device accounting for
`factors affecting
`output and typical
`delivery).
`o Pages 14-15
`(regarding the
`OptiNeb manual’s
`reported delivery
`rate).
`o Pages 10-13 (citing
`EX1107 (Gonda
`Reply Decl.), ¶¶20-
`27, 47-50 (assertions
`about nebulizer
`volumes, rates, and
`losses/efficiencies))
`o Page 15 and n.10
`(citing EX1107,
`¶¶53-54 (regarding
`expected delivered
`doses delivered
`output rates)).
`
`
`
`3
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`
`
`
`Parties’ Joint Errata
`
`Respectfully submitted,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Stephen B. Maebius/
`Stephen B. Maebius
`Registration No. 35,264
`Counsel for Patent Owner
`
`/Erik B. Milch/
`Erik B. Milch
`Registration No. 42,887
`Counsel for Petitioner
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date: May 6, 2022
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4
`
`
`
`IPR2021-00406
`U.S. Patent No. 10,716,793
`
`Parties’ Joint Errata
`
`CERTIFICATE OF SERVICE
`
`
`
`The undersigned hereby certifies that a copy of the foregoing Parties’ Joint
`
`Errata was served on counsel of record on May 6, 2022, by filing this document
`
`through the PTAB E2E System as well as delivering a copy via email to the
`
`counsel of record for the Petitioner at the following addresses:
`
`zLiquidiaIPR@cooley.com
`ielrifi@cooley.com
`emilch@cooley.com
`dkannappan@cooley.com
`
`
`Date: May 6, 2022
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Stephen B. Maebius/
`Stephen B. Maebius
`Foley & Lardner LLP
`
`4892-1928-0670.1
`
`5
`
`